Risk for Second Primary Cancer May Be No Higher With CAR T-Cell Versus Standard of Care
By Elana Gotkine HealthDay Reporter
THURSDAY, Sept. 12, 2024 -- The overall second primary malignancy (SPM) point estimate was 5.8 percent for patients receiving chimeric antigen receptor (CAR) T-cell therapy, according to a study published online Sept. 11 in Clinical Cancer Research.
Tobias Tix, from LMU Klinikum in Munich, and colleagues conducted a systematic review to delineate the frequency and subtypes of SPMs following CAR T-cell therapy in lymphoma and myeloma. A total of 326 SPMs were identified across 5,517 patients from 18 clinical trials and seven real-world studies.
The researchers found that the overall SPM point estimate was 5.8 percent with a median follow-up of 21.7 months. There were associations for SPM estimates with treatment setting (clinical trials > real-world settings), follow-up duration, and number of previous treatment lines. In a meta-regression model, these associations were confirmed as independent study-level risk factors for SPM. The risk for SPM was similar with either treatment strategy in a subgroup meta-analysis of four trials that randomly assigned patients to CAR T-cell therapy versus standard of care. In an analysis of SPM subtypes, the most common were hematologic malignancies, followed by solid tumors and nonmelanoma skin cancers (37, 27, and 16 percent, respectively). A small minority of events were T-cell malignancies (1.5 percent).
"By understanding the factors contributing to SPM development and implementing effective monitoring strategies, health care providers can optimize patient outcomes and ensure the long-term safety of CAR T-cell therapies," the authors write.
Several authors disclosed ties to the pharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted September 2024
Read this next
Exercise Helps Reduce Side Effects From Cancer Treatment
THURSDAY, May 1, 2025 -- Exercise mitigates adverse outcomes associated with cancer and its treatments, according to a review published online April 29 in the British Journal...
Outcomes With Immune Checkpoint Inhibitors Similar for Older, Younger Patients
TUESDAY, April 29, 2025 -- Patients with cancer aged 65 years and older receiving immune checkpoint inhibitors (ICIs) derive similar clinical outcomes as younger patients...
Prevalence of Most Cancer Risk Factors Unchanged Before, After Pandemic
THURSDAY, April 24, 2025 -- Smoking rates continued to decline during the COVID-19 pandemic, but other major risk factors for cancer remained stable, according to a study...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.